While tumor cells with BRAF mutations may be candidates for BRAF inhibitors, and those with KIT mutations seem to respond to tyrosine kinase inhibitors, TP53 mutated cells exhibit resistance to multiple therapies, including cisplatin, alkylating agents, antimetabolites, or anthracyclins [12–14]. This evidence concerns the gene BRAF and neoplasm.